SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.61-0.6%Nov 6 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (9035)9/2/2003 5:05:59 PM
From: Biomaven  Read Replies (1) of 52153
 
Erik,

Agreed on Roche - and of course their KOSN deal was another example of paying up for an early-stage compound.

I've been saying for a while that I've been impressed by the recent Roche partnering deals. But the rest of pharma is mostly stuck in the old model - give the biotech a million or two upfront and single digit royalties. But all you can get on those terms now are lower quality or highly speculative projects.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News